DIRS.INFO The most relevant business & tech news

☆ Generative AI will be designing new drugs all on its own in the near future
▼ + stars: | 2024-05-05 | by ( Trevor Laurence Jockims | ) www.cnbc.com time to read: +12 min

An analogy for understanding the development of AI drugs can be found in the mechanisms of ChatGPT. As a result, it's a drug discovery process that has a 90% failure rate. Some of the noted flaws of generative AI, its propensity to "hallucinate" for example, could prove to be powerful in drug discovery. AI is learning to distinguish drugs from non-drugs, and to create new drugs, in the same way that ChatGPT can create sentences, Ellington said. Now, AI models are helping narrow down the possibilities, so scientists more quickly know the optimal modifications to try.

Persons: ChatGPT, Kimberly Powell, Google's, —, AlphaFold, Powell, Rau, Lilly, Eli Lilly, Diogo Rau, It's, Amgen, Andy Ellington, Ellington, Daniel Diaz, Diaz, We've Organizations: Nvidia, CNBC Technology, Summit, University of Texas, Austin, NVIDIA, biosciences, UT's Institute, Foundations of Machine, Cadence Locations: Nature

☆ This rare muscle disease play can rally more than 50%, BofA says
▼ + stars: | 2024-05-03 | by ( Alex Harring | ) www.cnbc.com time to read: +2 min

Avidity Biosciences stock has more room to run thanks to the company's pipeline of multiple treatments for rare muscle disorders, according to Bank of America. Avidity has a therapeutic platform — antibody oligonucleotide conjugates — that was well-received at the time it went public in 2020, Meacham said. But shares were hurt by a clinical hold on Avidity's leading program for treating an uncommon muscle disorder, DM1. The program, tested in the Marina trial, recently saw long-term data that has "helped lift that key overhang on the stock," Meacham said. Those catalysts are tied to two other drugs in the muscle disorder space that are expected to report data this year, according to Meacham.

Persons: Geoff Meacham, Meacham Organizations: Biosciences, Bank of America Locations: San Diego, Thursday's

☆ Here are Friday's biggest analyst calls: Apple, Target, Coinbase, Berkshire Hathaway, Estee Lauder & more
▼ + stars: | 2024-05-03 | by ( Michael Bloom | ) www.cnbc.com time to read: +6 min

JPMorgan upgrades Williams-Sonoma to neutral from underweight JPMorgan said in its upgrade of the stock that the home furnishings category is stabilizing. "We are downgrading shares of EXPE to Mkt Perform from OP with a target price of $145 vs. $165 previously." JPMorgan upgrades Joby to neutral from underweight JPMorgan said its bear thesis has largely played out for the aviation company. Guggenheim reiterates Target as buy Guggenheim said investors should buy the dip in shares of Target . Morgan Stanley downgrades Estee Lauder to equal weight from overweight Morgan Stanley said it sees a slower recovery for shares of Estee Lauder .

Persons: Stifel, Wells, Truist, OLLI, Guggenheim, Tim Cook, William Blair, Amgen, Jefferies, We've, Ari sta, it's, Morgan Stanley downgrades Estee Lauder, Morgan Stanley, Estee Lauder, TD Cowen, Parsons, Bernstein, Oppenheimer, CFRA, Berkshire Hathaway Organizations: RBC, FTAI Aviation, Pacific, Union Pacific, JPMorgan, Williams, WSM, BMO, Bank of America, Apple, Kiniksa Pharmaceuticals, JOBY, Guggenheim, Target, Citi, MCW, Arista, PSN, Avidity, ~$ Locations: Sonoma, EXPE, GEICO

☆ Stocks making the biggest moves midday: Apple, Expedia, Block, Live Nation and more
▼ + stars: | 2024-05-03 | by ( Hakyung Kim | ) www.cnbc.com time to read: +3 min

Check out the companies making headlines in midday trading: Apple — The tech giant jumped more than 6% after announcing it would repurchase $110 billion in shares . That topped analysts' estimates for earnings of $1.50 per share on revenue of $90.01 billion, per LSEG. Block — The payment services provider added 1% after posting first-quarter results that beat analysts' expectations. Live Nation Entertainment — Shares jumped 9% on the back of better-than-expected first-quarter revenue. However, the company beat analysts' expectations for the first quarter.

Persons: LSEG, Piper Sandler, FactSet, Eli Lilly, Cloudflare, Jefferies, —, Alex Harring, Lisa Kailai Han, Michelle Fox, Pia Singh Organizations: Apple, Management, Wall Street, BMO Capital Markets, Expedia, Holdings, bullish Bank of America, Novo Nordisk, Arista Networks, Arista Locations: Thursday's, billings

☆ A longevity researcher is facing backlash for claiming to 'reverse aging.' Scientists say there's no consensus on what it means.
▼ + stars: | 2024-04-28 | by ( Lakshmi Varanasi | ) www.businessinsider.com time to read: +4 min

Read previewHarvard researcher Dr. David Sinclair has found himself at the center of controversy within the longevity community. He's also earned his share of critics who say his research isn't always backed up by sufficient evidence. Animal Biosciences reissued a press release walking back the "reverse aging" claim. But scientists in the field say the issue is even more fundamental: There's no way to reverse aging, much less measure it. That means debates about the semantics of aging will only become more relevant to our daily lives.

Persons: —, David Sinclair, Sinclair, He's, Dr, Nir Barzilai, Matt Kaeberlein —, Matt Kaeberlein, Barzilai, it's, it'll, Andrea Maier, Jeff Bezos, Peter Thiel Organizations: Service, Business, Street Journal, Animal Biosciences, Newsweek, The Academy for Health, Academy for Health, Academy, National Institute, Aging, MIT Technology, National University of Singapore, Longevity

☆ Wells Fargo becomes bullish on this biotech company
▼ + stars: | 2024-04-24 | by ( Hakyung Kim | ) www.cnbc.com time to read: +1 min

Neurocrine Biosciences ' drug pipeline is turning a corner and the company will be "knocking on the doors of the large-cap club" soon, according to Wells Fargo. Bansal forecasts the company's congenital adrenal hyperplasia treatment, crinecerfont, will achieve $1.5 billion in peak sales, topping his prior $1.1 billion estimate. "We think [the] Crinecerfont [opportunity] is underappreciated as the Street is only giving credit for $500-$700M peak opportunity." Bansal said this drug could open "a whole new chapter" of a $1.2 billion peak sales opportunity. The NBI-'845 treatment could be "another blockbuster opportunity," Bansal said, citing the treatment's once-daily administration as a factor in his assessment.

Persons: Mohit, Bansal, Takeda, — CNBC's Michael Bloom Organizations: Biosciences Locations: Wells Fargo

☆ How R&D Funding Is Making the UK a Global Leader in Science
▼ + stars: | 2024-04-17 | by ( Sponsor Post | ) www.businessinsider.com time to read: +8 min

Exscientia's growth was bolstered by government support: The company didn't take venture funding until 2019. Exscientia wouldn't be where it was, Taylor said, without the support of the UK higher education system and government funding. Martin Tangney, the chief scientific officer of Edinburgh-based Celtic Renewables, said the £11 million of funding his company received in 2015 from the UK government was "pivotal." Advertisement"We really believe … [that] basically, soon all drugs are going to be created with AI," Taylor said. AdvertisementClick here to find out more about how your business can benefit from Research & Development in the UK.

Persons: Ben Taylor, Achilles, Taylor, —, We've, Smith, Nephew, we've, Martin Tangney, isn't, ABE, you've, Tangney Organizations: Nasdaq, University of Dundee, AstraZeneca, COVID, Celtic Renewables, biosciences, Department for Science, Innovation & Technology, Edinburgh Napier University, Government, Renewables, Research & Development, Insider Studios, UK's Department for Business & Trade, Innovation, Technology Locations: Oxford, UK, Edinburgh, Scotland, Ireland, Japan, America, India, Grangemouth

Morgan Stanley raised its price target on Nvidia, calling for more than 15% upside going forward. — Lisa Kailai Han 5:53 a.m.: Jefferies lowers Tesla price target, cites 'self-inflicted' wounds Tesla's troubles may not be over yet, according to Jefferies. The investment firm kept its hold rating on the electric vehicle maker and lowered its price target to $165 from $185. Jefferies analyst Philippe Houchois also said Tesla is plagued by shifting product priorities. — Lisa Kailai Han 5:53 a.m.: Morgan Stanley raises Nvidia price target Nvidia has already rallied more than 72% in 2024.

Persons: Morgan Stanley, Jefferies, Patrick Cunningham, Erik Fyrwald's, Cunningham, — Lisa Kailai Han, Zillow, John Colantuoni, Colantuoni, Scott Schoenhaus, Schoenhaus, Lisa Kailai Han, Hess, Betty Jiang, CVX, Jiang, Tesla, Philippe Houchois, Joseph Moore, Moore, — Fred Imbert Organizations: CNBC, Nvidia, Citi, Management, & Biosciences, Jefferies, National Association of Realtors, Markets, GDRX, Barclays, Chevron, NVIDIA, AMD Locations: Tuesday's, China

☆ Record levels of funding propel Denver-Boulder to the top of the life sciences market
▼ + stars: | 2024-04-08 | by ( Chris Dilella | ) www.cnbc.com time to read: +7 min

The Denver-Boulder region is rapidly emerging as a major hub for the life sciences industry, attracting companies that develop cutting-edge medical treatments and technologies. Life sciences research aims to understand living things, from cells to our planet, to improve health, food and the environment. Founded in 2003, the Bioscience Association supports the growth of life sciences, with a focus on access to capital, education, networking and more. A recent CBRE report found Denver-Boulder to be the top U.S. life sciences real estate market, fueled by record investment from venture capitalists and the National Institutes of Health. Entrepreneurial successThe recent surge in venture capital flowing into Denver-Boulder builds on the area's proven track record of success over the past several decades.

Persons: Tim Schoen, BioMed, Schoen, Elyse Blazevich, Kevin Koch, Koch, Edgewise, We've, Dan LaBarbera, LaBarbera, Dr Organizations: BioMed, CNBC, Blackstone, Flatiron, Enveda Biosciences, Denver, Boulder, Colorado Bioscience Association, Bioscience Association, National Institutes of Health, U.S, Pfizer, Therapeutics, University of Colorado, Edgewise Therapeutics, Research, University of Colorado's Anschutz Medical, Center, Drug, Center for Drug, for Drug, Anschutz Medical Locations: CNBC's, Denver, Boulder, Diego, Boulder , Colorado, San Diego, San Francisco, Seattle, Boston, Cambridge, Massachusetts, Aurora, Rocky, Colorado, Boulder ., Denver's

☆ Sam Altman's mission to increase human lifespan with a $180 million shipping container experiment at Retro Biosciences
▼ + stars: | 2024-03-23 | by ( Hilary Brueck | ) www.businessinsider.com time to read: +11 min

Called Retro Biosciences, the startup's goal is simple yet supremely ambitious: Add 10 healthy, enjoyable years onto the back end of our lifetimes. But Retro Biosciences actually fits quite neatly into Altman's futuristic worldview. Retro BiosciencesRetro Biosciences sits about 30 miles south of OpenAI's San Francisco headquarters, where ChatGPT was hatched. Joe Betts-LaCroix is the CEO of Retro Biosciences. There are things we already know work super well to improve human longevity, like exercise, diet, faith, and social support.

Persons: Sam Altman, he's, Elon Musk, Mark Zuckerberg, Altman, Instacart —, Joe Betts, LaCroix, isn't, Betts, Retro's, spry, Yamanaka, Shinya Yamanaka, it's, they've, Sora, Thiel, Jeff Bezos, Bezos, Yuri Milner, Billionaire Peter Thiel, He's, Aubrey de Grey, Christian Angermayer, biogerontologist Daniel Promislow, Altman's, Matt Buckley Organizations: Business, OpenAI, Biosciences, Harvard, MIT, Caltech, Extension, Apple, Stanford University, Retro, Bezos, Labs, Billionaire, Cambrian, Retro Biosciences, Bloomberg Locations: geroscience, Silicon Valley, OpenAI's San Francisco, Meta, Golden City, Retro.bio, Redwood City , California, San Diego

☆ It's comeback season for social media
▼ + stars: | 2024-03-23 | by ( Joi-Marie Mckenzie | Jordan Parker Erb | ) www.businessinsider.com time to read: +5 min

This story is available exclusively to Business Insider subscribers. But first: Social media is making a comeback. I'm not alone: Sharing on social media has tapered off, Business Insider reported back in 2023, but consuming content hasn't. Now social media platforms — Facebook, Instagram, TikTok, and others — are clamoring to get users to stay just a little while longer. It's clear social media isn't giving up without a fight — and right now, it seems we're OK with that.

Persons: —, Instagram, Tyler Le, edu, Mark Zuckerberg, I'm, Gen Z, Kate Middleton, BBC Studios Kate, Princess, Wales, she's, Read, Andrew Caballero, Reynold, Jenny Chang, Rodriguez Sam Altman, OpenAI, Altman, Pete Ballmer, Abanti Chowdhury, Steve Ballmer's, Pete, didn't, Kristen Wiig's, Joi, Marie McKenzie, Jordan Parker Erb, Dan DeFrancesco, Lisa Ryan Organizations: Service, Business, Dispatch Social, Facebook, BBC Studios, Aurora, Getty, Biosciences, Hulu, Netflix Locations: Finland's, Utsjoki, Lapland, New York

☆ Can the woolly mammoth really be resurrected? Scientists take a small step closer
▼ + stars: | 2024-03-09 | by ( Katie Hunt | ) edition.cnn.com time to read: +7 min

The stem cells will also make it easier for conservation scientists to study the Asian elephant’s unique biology. An Asian elephant stem cell line stained in different colors to highlight different elements. Courtesy ColossalEngineering a woolly mammoth hybridThe elephant stem cells also hold the key to the mammoth’s rebirth. The research team at Colossal has already analyzed the genomes of 53 woolly mammoths from ancient DNA recovered from fossils. The number of modifications needed to make an Asian elephant resistant to the cold would be broadly similar, he said.

Persons: George Church, Ben Lamm, Eriona, Eriona Hysolli, John Davidson “, ”, Hysolli, Oliver Ryder, Ryder, ” Ryder, Christopher P, Michel “, Ben’s, Lamm, “, That’s, We’ve, tramping, Colossal Organizations: CNN, Harvard University, Church, Dallas, Biosciences, Colossal, San Diego Zoo Wildlife Alliance, Colossal Biosciences, Christopher Locations: Dallas, ”, Siberia

☆ $1.5 billion startup says it's getting close to bringing the woolly mammoth back from the dead with elephant cells
▼ + stars: | 2024-03-07 | by ( Marianne Guenot | ) www.businessinsider.com time to read: +4 min

Read previewThe startup that wants to bring the woolly mammoth back from the dead said it is inching closer to its goal after a breakthrough in creating reprogrammed elephant stem cells. These include bringing back the woolly mammoth and the dodo. But elephant stem cells remained remarkably resistant to the process, per the statement. AdvertisementAfter tweaking the chemical composition of the mixture, Colossal Scientists say they've finally cracked it. Understanding how to turn tweak these elephant stem cells into cells from the extinct species will be another hurdle to tackle going forward.

Persons: —, Ben Lamm, Lamm, George Church, we've, Evan Appleton, Vincent Lynch, Lynch, Hysoli Organizations: Service, Colossal Biosciences, Business, Harvard, University at Buffalo, Science Locations: New York

☆ The breathtaking scope of Sam Altman's future AI empire
▼ + stars: | 2024-03-07 | by ( Darius Rafieyan | ) www.businessinsider.com time to read: +9 min

If Sam Altman is to achieve his dream of artificial general intelligence in his lifetime, that number will need to double or triple every year for the foreseeable future. These wide-ranging plans for global transformation go far beyond Altman's role as the CEO of generative AI behemoth OpenAI, developer of ChatGPT. EnergyThe first pillar of Altman's grand unified theory of the future rests on energy. Headlining the event was company chairman and investor Sam Altman, who appeared via video call projected on a towered cineplex. And Altman's AGI empire extends beyond just the energy and raw material required to build AGI.

Persons: Sam Altman, he's, Altman, it's, Max, Jack, Sam himself, Sam, David Kirtley, Helion, He's, Joe Betts Lacroix, Lacroix, where's, Joe Biden, Tade Oyerinde, Oyerinde, Ali Ghodsi, Ghodsi Organizations: Nvidia, Business, Elon, Altman, OpenAI, Energy, Bloomberg, Concorde, Wall Street, Retro Biosciences, Capitol, PAC Locations: Silicon Valley, OpenAI, Davos, New York, Redmond , Washington, Washington

☆ How sleep can affect diabetes risk, according to new study
▼ + stars: | 2024-03-05 | by ( Kristen Rogers | ) edition.cnn.com time to read: +5 min

Sleep is an important lifestyle factor in reducing risk for type 2 diabetes, a new study has found. In terms of risk for type 2 diabetes, there wasn’t a significant difference between those with normal sleep and those who slept six hours. And even for those who ate the healthiest, their diet didn’t offset the effects of insufficient sleep on diabetes risk. The findings are also based on participants’ recollections of their food and sleep habits, according to the study. Confirming a causal relationship “would require randomized trials intervening on sleeping habits to increase sleep time and see if this reduces risk of diabetes in those at risk, e.g.

Persons: CNN —, Dr, Diana Nôga, ” Nôga, ”, Leana Wen, Wen wasn’t, ” Wen, Naveed Sattar, ” Sattar, Wen Organizations: CNN, JAMA, biosciences, Uppsala University, Lighthouse Films, George Washington University Milken Institute School of Public Health, University of Glasgow Locations: Sweden, United Kingdom, Scotland, “

☆ Here are Friday's biggest analyst calls: Nvidia, Apple, Dell, Netflix, Micron, Broadcom, Eli Lilly, New York Community Bancorp & more
▼ + stars: | 2024-03-01 | by ( Michael Bloom | ) www.cnbc.com time to read: +8 min

"We are initiating coverage of Evolent Health with an Outperform rating and $45 price target." Goldman Sachs downgrades Estee Lauder to neutral from buy Goldman downgraded the stock and said it's under "sizeable pressure." "We are upgrading Annexon (ANNX shares) to Overweight from Neutral and establishing a December 2024 price target of $11." Bank of America reiterates Eli Lilly as buy Bank of America raised its price target on the stock to $1000 per share from $800. "Following 4Q23 earnings we are upgrading GoodRx from Neutral to Overweight and increasing our December 2024 price target from $7 to $10."

Persons: Davidson, Campbell, Morgan Stanley, JD, TD Cowen, Parker, Dell, Goldman Sachs, Goldman, Louise Singlehurst, Tom Ford, Jefferies, Root, AVGO's, Stephens, Vita Coco, COCO, Piper downgrades, Piper, Redburn, Oppenheimer, Daiwa, Morgan Stanley downgrades Flywire, Goldman Sachs downgrades Estee Lauder, Estee Lauder, Dwight, Wells, Eli Lilly, Lilly, D.A Organizations: Apple, Vulcan, Merck, Vertex Pharmaceuticals, Bank of America, Broadcom, York Community Bancorp, Netflix, Micron, Mizuho, MU, Citi, EV, Health, Nvidia, Dwight, Hewlett Packard Enterprises, JPMorgan, biosciences, " Bank of America Locations: York, Davidson, Oshkosh, Minneapolis , MN

☆ 'This is the mental health moment': Innovation and M&A are helping to boost these stocks to new heights
▼ + stars: | 2024-02-19 | by ( Michelle Fox | ) www.cnbc.com time to read: +14 min

There's been a lot of chatter about the mental health crisis since the Covid-19 pandemic. Attention to a long-time crisis The mental health crisis is nothing new. However, there has also been a growing awareness and acceptance of mental health illnesses over the past decade, said Canaccord Genuity analyst Richard Close. "There's been recognition that mental health has a significant impact on a person's overall health," he said. "This is the mental health moment," said Dr. Ken Duckworth, NAMI's chief medical officer and author of "You Are Not Alone: The NAMI Guide to Mental Health."

Persons: There's, Covid, Peter Micca, AbbVie, Emraclidine, Myers Squibb, Karuna, Marc Goodman, Canaccord, Richard Close, MacKenzie Scott, Ken Duckworth, NAMI, Deloitte's Micca, William Blair, Myles Minter, Minter, Auvelity, Leerink's Goodman, Ashwani Verma, Verma, Goodman, BioHaven, Cerevel, Neumora, tardive, David Song, BetterHelp, psychedelics Johnson, Johnson, Spravato, Blair's Minter, Axsome, Micca, Michael Bloom Organizations: Institute for Health Metrics, Deloitte, Cerevel Therapeutics, Karuna Therapeutics, Bristol Myers, Leerink Partners, Centers for Disease Control, National Alliance, Mental, Mental Health, Wall Street, Therapeutics, Neumora Therapeutics, UBS, Karuna, Cellular Therapies, Xenon Pharmaceuticals, Neurocrine Biosciences, Acadia Pharmaceuticals, Tema Neuroscience, Axsome Therapeutics, Acadia Healthcare, BetterHelp, CNBC, pharma, Cellular Locations: Covid, Bristol, XEN1101, Acadia, Tema

☆ 4 of our stocks report earnings next week. Here's what we want to see from each
▼ + stars: | 2024-02-17 | by ( Zev Fima | ) www.cnbc.com time to read: +9 min

A hotter-than-expected consumer price index on Tuesday sent stocks reeling, with the Dow posting its biggest drop in a year. Stocks bounced back over the next two days, helped by a softer retail sales report , only to slump again on Friday's hot producer price index for January. As we said this week, we're not overly concerned with the hotter-than-expected inflationary readings. Earnings season picks back up for the Club next week, with four holdings set to report quarterly results. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade.

Persons: Wall, Stocks, we're, Palo, Fortinet, BCH's Bausch, Management doesn't, Dana, Bausch, Dr Pepper, Diana Shipping, Jim Cramer's, Jim Cramer, Jim, Jensen Huang, Walid Berrazeg Organizations: Dow Jones Industrial, Nasdaq, Dow, Federal Reserve, Club, Palo Alto, Palo, billings, Nvidia, Amazon, Microsoft, Bausch Health, Coterra Energy, Management, NYSE, Walmart, Axsome Therapeutics, Barclays Bank, Armstrong World Industries, Ceragon Networks, Tri Pointe Homes, Dana Incorporated, DigitalBridge, Oil States International, Systems, Allegion, CenterPoint Energy, Equitrans Midstream Corporation, Expeditors International of Washington, Alto Networks, SolarEdge Technologies, Enovix Corporation, Caesars Entertainment, Diamondback Energy, Toll, Ternium S.A, Celanese Corp, Chesapeake Energy, CVR Energy, Reserve, Vertiv Holdings Co, Properties Trust, Devices, HSBC Holdings plc, HSBC, Lomb, Sinclair Corporation, Pagaya Technologies, Gibraltar Industries, Garmin, NVIDIA, Rivian Automotive, Sunnova Energy International, Bros, Apache, Oil, Suncor Energy, Co, FNF, Sciences, Coeur D'Alene Mines, Trip.com, Joby Aviation, Resources, Alamos, Jackson, Nutrien, NTR, Pan, Sm Energy Company, Health, Newmont, Nikola Corporation, Cheniere Energy, Fiverr, Natural Resources, Point Credit, Lantheus Holdings, Builders, Grab Holdings, NICE, Dominion Energy, Harmony Biosciences Holdings, Teck Resources Limited, Intellia Therapeutics, Energy, Booking Holdings, Intuit, Semiconductor, Nation Entertainment, Vale S.A, Rocket Companies, Warner Bros ., AerCap Holdings, Natural Holdings, Calumet Specialty Products Partners, Frontier Communications, Jim Cramer's Charitable, CNBC, Lightrocket, Getty Locations: billings, Palo Alto, China, Xifaxan, Tri Pointe, Avista, Gibraltar, Coeur D'Alene, Pan American, Teck, Vale

☆ A former OpenAI exec says AI could be the last technology humans ever invent
▼ + stars: | 2024-01-17 | by ( Katherine Tangalakis-Lippert | ) www.businessinsider.com time to read: +11 min

So now you start compounding the implications on life sciences, and biosciences and it gets really, really exciting. I will say this, I don't think that it is currently popular to espouse an overwhelmingly positive sentiment, because I think it is seen as naive. I think we are so wrapped up in the Terminator Skynet idea, and I just don't think that's even remotely interesting given what we think we're building. I point to nuclear as the best example of how one policy, especially influenced by public perception, can have a really, really incredible consequence on the human experience. I think there is not enough attention paid to the issue of AI versus AI.

Persons: Zack Kass, Kass, Santa Barbara, Sam, Altman, I've, we're Organizations: Artificial Intelligence, biosciences, Artificial General Intelligence Locations: Santa, China

☆ A scientist explains what would happen if all the fish in the ocean disappeared
▼ + stars: | 2024-01-08 | by ( Kory Evans | The Conversation | ) www.businessinsider.com time to read: +5 min

So what would happen to Earth if all the fish in the ocean suddenly disappeared? NOAA, Kevin LinoI'm a scientist who studies fish, their diversity, and all the ways they contribute to ocean environments. Fish as foodFish play important roles as both predators and prey in ocean ecosystems. Related storiesIn coral reef ecosystems, small fish are eaten by larger fish and other marine animals. AdvertisementIn coral reef ecosystems, plant-eating fish control the growth of algae by constantly grazing it down.

Persons: Fish, Kevin Lino I'm, Rogers, parrotfish, Kory Evans Organizations: Service, Fisheries, NOAA, biosciences, Rice University Locations: They're, United States, parrotfish

☆ Stocks making the biggest moves after hours: Box, MongoDB, Dave & Buster's and more
▼ + stars: | 2023-12-05 | by ( Lisa Kailai Han | ) www.cnbc.com time to read: +2 min

Box — The cloud company plummeted 11% after reporting fiscal third-quarter adjusted earnings of 36 cents per share on revenue of $261.5 million. This was lower than FactSet's analyst expectations of 38 cents per share on $262.4 million of revenue. MongoDB — The database stock shed 4% despite MongoDB beating analysts' expectations in its third-quarter earnings. The company's $167 million revenue was also above the forecast $164 million. Dave & Buster's — The stock slipped 3% after the company posted third-quarter revenue of $466.9 million, lower than analysts' forecast for $473 million, per LSEG.

Persons: Asana, Buster's, LSEG Organizations: LSEG, Biosciences, U.S . Food, Drug Administration, crinecerfont, Toll Locations: U.S

☆ These tenbagger stocks are well liked by analysts and may rally even more
▼ + stars: | 2023-12-03 | by ( Lisa Kailai Han | ) www.cnbc.com time to read: +2 min

Over the last 10 years of market turbulence, there haven't been very many stocks that have seen a more than 1,000% compound return. Fewer still of these "tenbaggers," companies that have multiplied in value 10 times, have sizeable upside expectations ahead. The average analyst still sees potential upside of 40%. Early last month, Jefferies began research coverage of Celsius with a buy rating, citing several growth opportunities that lie ahead. With a 10-year compound total return of nearly 13,000%, chipmaker Nvidia was also at the top of the list.

Persons: Jefferies, Kaumil Gajrawala, Fred Imbert Organizations: CNBC, Holdings, PepsiCo, Nvidia, Microsoft, Semiconductor, Broadcom, Builders, Neurocrine Biosciences Locations: Florida

☆ Not so dead as a dodo: ‘De-extinction’ plan to reintroduce bird to Mauritius
▼ + stars: | 2023-12-01 | by ( Tom Page | ) edition.cnn.com time to read: +10 min

CNN —An audacious collaboration between geneticists and conservationists plans to bring back the extinct dodo and reintroduce it to its once-native habitat in Mauritius. But according to the partners, its return to Mauritius could benefit the dodo’s immediate environment and other species. The Nicobar pigeon, native to the coastal regions from the Andaman and Nicobar Islands, is the closest living relative to the dodo. Then it will edit the PGCs of a Nicobar so it expresses the physical traits of a dodo. “I have studied the dodo for many years, and there is still a lot to learn about this enigmatic bird,” he added.

Persons: dodo, Beth Shapiro, ”, Matt James, James, Holger Hollemann, Tatayah, ” Tatayah, “, dodos, Ben Birchall, Julian Hume, ” Hume, Ben Lamm, “ We’re Organizations: CNN, Colossal Biosciences, Mauritian Wildlife Foundation, Getty, Gorges, Colossal, “, White Rhino, Biosciences Locations: Mauritius, Rodrigues Island, Asia, Nicobar, Park, “ Mauritius, Aigrettes, Ile

☆ Stocks making the biggest moves before the bell: Alibaba, Applied Materials, Gap and more
▼ + stars: | 2023-11-17 | by ( Alex Harring | ) www.cnbc.com time to read: +3 min

Check out the companies making headlines in premarket trading. BJ's Wholesale Club — Shares retreated 4.6% in premarket trading after the company revised its expectation for comparable store sales in the fourth quarter amid shifting consumer behavior. Applied Materials — Shares slid 7.2% on Friday, a day after Reuters reported , citing sources, that the semiconductor company was under a Justice Department probe. Gap — The retailer soared 18.5% in premarket trading Friday. Marriott Vacations Worldwide — Shares of the timeshare company lost 2.5% after a Bank of America downgrade to underperform from neutral.

Persons: Alibaba, FactSet, Ross, Expedia, Morgan Stanley, — CNBC's Hakyung Kim, Sarah Min Organizations: BJ's Wholesale, Tenet Healthcare, Novant Health, Reuters, Justice Department, Ross, LSEG, Evercore ISI, Pacific Biosciences, UBS, biosciences, Barclays, Marriott, Bank of America Locations: Alibaba —, Carolina, California, GitLab

☆ Here are Friday's biggest analyst calls: Nvidia, Zoom, Expedia, Analog Devices, Cava, Roblox, Dick's & more
▼ + stars: | 2023-11-17 | by ( Michael Bloom | ) www.cnbc.com time to read: +7 min

Roth MKM downgrades ChargePoint to neutral from buy Roth said it's concerned about weak demand for charging equipment. UBS upgrades Pacific Biosciences to buy from neutral UBS said the biotech company has growth potential. Citi reiterates Microsoft as buy Citi said it's standing by its buy rating on the stock. Morgan Stanley upgrades Analog Devices to overweight from equal weight Morgan Stanley said the bottom is in sight for the semiconductor company. Truist initiates Dick's as buy Truist said in its initiation of the stock that it sees an attractive buying opportunity. "

Persons: Evercore, Roth, it's, CHPT, Wolfe, underperform Wolfe, RBLX, GitLab, Hubbell, Morgan Stanley, Carvana, Raymond James, Cava, Redburn, Piper Sandler, Piper, buybacks, Baird, Truist, Lululemon, Kimberly, Clark Organizations: EV, UBS, Pacific Biosciences, Citi, Microsoft, Barclays, JPMorgan, HSBC, UW, downgrades, Products, Nvidia, Coherus BioSciences, Goods, Zim Locations: ChargePoint, billings, 2Q24

Search resuls for: "Biosciences"

25 mentions found